

- ⁹²
93. The fusion protein of claim ⁶²~~62~~, wherein the stress protein is hsp71.
- ⁹³
94. The fusion protein of claim ⁵⁴~~54~~, wherein the stress protein is an Hsp100-200, an Hsp100, an Hsp90, Lon, an Hsp70, an Hsp60, TF55, an Hsp40, an FKBP, a cyclophilin, an Hsp20-30, C1pP, GrpE, Hsp10, ubiquitin, calnexin, or a protein disulfide isomerase.
- ⁹⁴
95. The method of claim ⁶⁴~~64~~, wherein the immune response is a cell mediated immune response.
- ⁹⁴
96. The method of claim ⁹⁵~~95~~, wherein the cell mediated immune response is a cell mediated cytolytic immune response.
- ⁹⁴
97. The method of claim ⁹⁵~~95~~, wherein the cell mediated immune response is a class I-restricted T cell response.
- ⁹⁴
98. The method of claim ⁹⁵~~95~~, wherein the cell mediated immune response is a class II-restricted T cell response.
- ⁹⁸
99. A fusion protein comprising a human papillomavirus (HPV) antigen, or an antigenic portion thereof, and a stress protein or a portion thereof, wherein the fusion protein induces an immune response to the HPV antigen in a mammal to whom the fusion protein is administered.
- ⁹⁹
100. The fusion protein of claim ⁹⁹~~99~~, wherein the HPV antigen is an E6 protein.
- ⁹⁹
101. The fusion protein of claim ⁹⁹~~99~~, wherein the HPV antigen is an E7 protein.
- ⁹⁹
102. The fusion protein of claim ⁹⁹~~99~~, wherein the HPV antigen includes a CTL epitope.
- ¹⁰²
103. The fusion protein of claim ¹⁰²~~102~~, wherein the CTL epitope is a class I-restricted T cell epitope.

¹⁰³
104. The fusion protein of claim ¹⁰², wherein the CTL epitope is a class II-restricted T cell epitope.

¹⁰⁴
105. The fusion protein of claim ⁹⁹, wherein the stress protein is a bacterial stress protein.

¹⁰⁵
106. The fusion protein of claim ⁹⁹, wherein the stress protein is an Hsp100-200, an Hsp100, an Hsp90, Lon, an Hsp70, an Hsp60, TF55, an Hsp40, an FKBP, a cyclophilin, an Hsp20-30, C1pP, GrpE, Hsp10, ubiquitin, calnexin, or a protein disulfide isomerase.

¹⁰⁶
107. The fusion protein of claim ⁹⁹, wherein the stress protein is a mycobacterial stress protein.

¹⁰⁷
108. The fusion protein of claim ¹⁰⁷, wherein the stress protein is hsp65.

¹⁰⁸
109. The fusion protein of claim ¹⁰⁷, wherein the stress protein is hsp71.

¹⁰⁹
110. The fusion protein of claim ⁹⁹, wherein the immune response is a cell mediated immune response.

¹¹⁰
111. The fusion protein of claim ¹¹⁰, wherein the cell mediated immune response is a cell mediated cytolytic immune response.

¹¹¹
112. The fusion protein of claim ¹¹⁰, wherein the cell mediated immune response is a class-I restricted T cell response.

¹¹²
113. The fusion protein of claim ¹¹⁰, wherein the cell mediated immune response is a class II-restricted T cell response.

¹¹³114. A composition comprising the fusion protein of claim ⁹⁸99 and a pharmaceutically acceptable excipient, carrier, diluent, or vehicle.

¹¹⁴115. A method of preventing or treating an HPV infection in a mammal, the method comprising administering the fusion protein of claim ¹¹⁸99 to the mammal in an amount effective to induce an immune response against the antigen.

¹¹⁵116. The method of claim ¹¹⁹115, wherein the fusion protein is administered in combination with a pharmaceutically acceptable excipient, carrier, diluent, or vehicle.

¹¹⁶117. The method of claim ¹²⁰115, wherein the immune response is a cell mediated immune response.

¹¹⁷118. The method of claim ¹²¹117, wherein the cell mediated immune response is a cell mediated cytolytic immune response.

¹¹⁸119. The method of claim ¹²²117, wherein the cell mediated immune response is a class I-restricted T cell response.

¹¹⁹120. The method of claim ¹²³117, wherein the cell mediated immune response is a class II-restricted T cell response.

¹²⁰121. A method of preventing or treating an HPV infection in a mammal, the method comprising administering the fusion protein of claim ⁹⁷100 to the mammal in an amount effective to induce an immune response against the antigen.

¹²¹122. A method of preventing or treating an HPV infection in a mammal, the method comprising administering the fusion protein of claim ¹⁰⁰101 to the mammal in an amount effective to induce an immune response against the antigen.

Applicant : Lee A. Mizzen *et al.*
Serial No. : 08/977,787
Filed : November 25, 1997
Page : 5

Attorney Docket No.: 12071-011002

122

123. The fusion protein of claim 101, wherein the stress protein is mycobacterial Hsp65.

123

124. A method of preventing or treating an HPV infection in a mammal, the method comprising administering the fusion protein of claim 123 to the mammal in an amount effective to induce an immune response against the antigen.--